Expert Interview
Discussing Concert Pharmaceuticals’ THRIVE-AA1 study results of CTP-543 in alopecia areata
Ticker(s): CNCEA dermatologist with experience in treating moderate to severe alopecia areata, following recent Phase 3 results.
Please describe your practice as a clinician,how many patients with alopecia areata do you treat on a yearly basis? Could you walk us through the standard of care, and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
How much of an unmet need is there for moderate to severe alopecia areata patients? Could you please debate the recent Phase 3 results, where, for patients with an absolute Severity of Alopecia Tool (SALT) score less than 95 at baseline, 43% and 57% of the 8 mg twice-daily and 12 mg twice-daily deuruxolitinib dose groups, respectively, achieved a SALT score of 20 or less at Week 24 -vs the other disease severity and durations presented?
How much use do you see for CTP-543 in the near future? How likely are you to prescribe it to your patients?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
